ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Advanced Search

Urinary Biomarkers- CXCL9 and CXCL10 for Non-Invasive, Early Diagnosis of Rejection in Pediatric Renal Transplantation

R. P. George1, B. Hanberry2, I. Dave2, B. Lee2, R. Garro1, C. McCracken2, B. Warshaw1

1Pediatrics, Emory University and Children's Healthcare of Atlanta, Atlanta, GA, 2Pediatrics, Emory University, Atlanta, GA

Meeting: 2019 American Transplant Congress

Abstract number: A172

Keywords: Biopsy, Kidney transplantation, Pediatric, Rejection

Session Information

Date: Saturday, June 1, 2019

Session Name: Poster Session A: Biomarkers, Immune Monitoring and Outcomes

Session Time: 5:30pm-7:30pm

 Presentation Time: 5:30pm-7:30pm

Location: Hall C & D

Related Abstracts
  • Diagnostic Value and Confounding Factors of Urinary Biomarkers in the Non-Invasive Screening of Renal Allograft Inflammation
  • Urinary CXCL10 Independently Improves the Noninvasive Diagnosis of Antibody-Mediated Kidney Allograft Rejection

*Purpose: Renal transplantation is the treatment of choice for End Stage Renal Disease, but requires strict medication adherence and lifelong surveillance for rejection, infection and allograft dysfunction. Renal biopsy remains the gold standard for diagnosing allograft injury but its invasive nature is challenging, especially in children. A compelling need hence exists, for validating non-invasive biomarkers, to detect subclinical rejection early, and allow safe modification of medications based on immunologic risk, to not only prevent rejection, but also reduce excessive medication burden or side effects. Urinary CXCL9 and CXCL10 are two such promising biomarkers, but prospective trials validating their clinical use, especially in children are limited.

*Methods: We performed a cross-sectional analysis of 46 urine samples obtained from 36 pediatric renal transplant recipients, who had kidney biopsies (for-cause or protocol) done at the same time. Urine was analyzed using a solid-phase bead-array assay for the interferon gamma-induced chemokines CXCL9 and CXCL10, in triplicate, using the commercially available CXCL9 and CXCL10 DuoSet ELISA (R&D Systems, Minneapolis, MN) as per manufacturer’s instructions. Urinary chemokine levels were matched to pathologic findings in renal biopsies, classified as acute rejection- borderline or more severe histologic findings (AR), BK nephritis (BKN), or interstitial fibrosis, tubular atrophy (IFTA).

*Results: In children experiencing AR, there was an elevation of both CXCL9 (p=0.041) and CXCL10 (p=0.024) but not in stable allograft recipients, or recipients with IFTA (Figure 1). Only 1 patient had biopsy proven BKN and showed increase in both biomarkers, as compared to patients with stable allograft. Using cut-point analysis for AR, BK viremia and donor specific antibody, we determined values for CXCL9 and CXCl10 to identify patients with allograft inflammation, with 81% sensitivity and 84% negative predictive value.

*Conclusions: These data show that urine chemokine monitoring can help non-invasively screen and identify pediatric renal transplant recipients with renal allograft inflammation. In the future, we plan to use CXCL9 and CXCl10 cut-points to stratify patients into immune-quiescent or immune-active groups, to predict outcomes and either lower medication burden or escalate monitoring/therapy.

 border=

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

George RP, Hanberry B, Dave I, Lee B, Garro R, McCracken C, Warshaw B. Urinary Biomarkers- CXCL9 and CXCL10 for Non-Invasive, Early Diagnosis of Rejection in Pediatric Renal Transplantation [abstract]. Am J Transplant. 2019; 19 (suppl 3). https://atcmeetingabstracts.com/abstract/urinary-biomarkers-cxcl9-and-cxcl10-for-non-invasive-early-diagnosis-of-rejection-in-pediatric-renal-transplantation/. Accessed January 16, 2021.

« Back to 2019 American Transplant Congress

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Subtherapeutic Low Tacrolimus Trough Levels (≤3.5 Ng /ml) Are A Risk Factor For Acute Rejection And Creatinine Doubling.
  • Penis Transplantation: First U.S. Experience.
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Live Related Kidney Transplant Experience in Abuja, Nigeria – First Eight Cases Ever.
  • Subtherapeutic Low Tacrolimus Trough Levels (≤3.5 Ng /ml) Are A Risk Factor For Acute Rejection And Creatinine Doubling.
  • Penis Transplantation: First U.S. Experience.
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Kidney Dialysis after Heart Transplantation: The Short and Long Term Outcomes
  • Penis Transplantation: First U.S. Experience.
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Evidence of a Clinically Significant Drug-Drug Interaction between Cannabidiol and Tacrolimus: A Case Report
  • Kidney Dialysis after Heart Transplantation: The Short and Long Term Outcomes

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2021 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.